In today’s briefing:
- Forian’s Founder-Led Consortium Proposes $2.10/Share Buyout Amid Potential for Higher Offer
- Mesoblast (MSB AU): Secures New Fund Amid Ongoing Commercialization of Ryoncil and Pipeline Progress
- Merck & Co.: Why Its Oncology Pipeline Development Is Worth WATCHING OUT FOR!
- Pre-IPO Nanjing Perlove Medical Equipment – Valuation Should Be Lower than Peers
- NRXBF: US Patent Awarded for Cell Technology
- Repligen Corporation: Powering Innovation With Game-Changing FlowVPX & PAT Integration!
- Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?
- Universal Health Services: A Closer Look At Its Payer Dynamics
- FBLG: Advancing Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies
Forian’s Founder-Led Consortium Proposes $2.10/Share Buyout Amid Potential for Higher Offer
- Forian received a $2.10/share go-private proposal from a consortium controlling 63% of the company; no premium offered.
- The company has a strong cash position, positive cash flow, and benefits from AI era tailwinds, suggesting limited downside.
- The two-step merger structure aims for 90% ownership, bypassing lengthy proxy processes and minimizing minority shareholder resistance.
Mesoblast (MSB AU): Secures New Fund Amid Ongoing Commercialization of Ryoncil and Pipeline Progress
- Mesoblast Ltd (MSB AU) entered into convertible note subscription agreements with SurgCenter principals and existing shareholders, Gregory George and William Gueck, to issue up to $50M of unsecured convertible notes.
- The maturity date of the convertible notes will be five years after the first issuance of notes. The convertible notes have a coupon of 5% p.a. on the face value.
- Mesoblast recorded maiden revenue of $13.2M from Ryoncil in FY25. Current revenue stream is anticipated to expand based on Ryoncil performance for existing as well as upcoming indications.
Merck & Co.: Why Its Oncology Pipeline Development Is Worth WATCHING OUT FOR!
- Merck & Co., Inc.’s Q2 2025 earnings offered a detailed insight into the company’s current performance, pipeline progress, strategic initiatives, and future outlook.
- Key figures showed that Merck faced a slight decline in total revenue, registering $15.8 billion, which reflected a 2% decrease both nominally and after adjusting for currency fluctuations.
- A significant factor influencing this decline was the reduction in GARDASIL sales in China, but excluding the Chinese market, Merck’s global growth stood at 7%, driven by strengths in oncology, new product launches like WINREVAIR and CAPVAXIVE, and Animal Health.
Pre-IPO Nanjing Perlove Medical Equipment – Valuation Should Be Lower than Peers
- Perlove’s strategy is high cost effectiveness to compete for market share. Although Perlove has achieved localization of some core components, detectors and algorithms of high-end equipment still rely on imports
- Due to the lack of high-end product line layout, the positioning of mid-to-low end products makes it difficult for Perlove to obtain brand premium, thereby affecting profit margin performance.
- Under the logic of import substitution, United Imaging and Wandong will benefit more than Perlove. Valuation of Perlove should be lower than United Imaging and Wandong.
NRXBF: US Patent Awarded for Cell Technology
- NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.
- The technology involved also has the potential to more efficiently get other treatments to the needed area.
- The company announced that the US Patent Office has issued a Notice of Allowance for a patent covering NurExone’s proprietary process for producing exosomes-further validating the uniqueness of the product and securing the right to it.
Repligen Corporation: Powering Innovation With Game-Changing FlowVPX & PAT Integration!
- Repligen Corporation reported strong financial results for the second quarter of 2025, driven by a 17% organic non-COVID revenue growth, which is the highest rate since 2022.
- This growth was bolstered by several segments within the company, with Chromatography and Filtration leading the way.
- Demand for consumables remains healthy, and high-teens growth in capital equipment was noted, indicating a solid rebound and strong market interest.
Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?
- Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various segments.
- The company, which specializes in heart valve technologies and structural heart therapies, showcased a notable double-digit sales growth, driven by the dynamic expansion of its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines.
- Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
Universal Health Services: A Closer Look At Its Payer Dynamics
- Universal Health Services (UHS) reported its earnings for the second quarter of 2025, showing a mixed performance across its segments.
- The company disclosed net income of $5.43 per diluted share and an adjusted net income of $5.35 after certain adjustments.
- On a same-facility basis, adjusted admissions in acute care hospitals increased by 2.0% compared to the prior year.
FBLG: Advancing Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies
- On September 10, 2025, FibroBiologics, Inc. (FBLG) announced significant advancements in the company’s Bone Marrow Organoid platform that could lead to new treatment options for blood cancers and age-related immune decline.
- The company shared that pre-IND animal studies in a xenograft melanoma mouse model showed significant tumor reduction following transplantation of bone marrow organoids.
- The organoid platform has the capability to allow for efficient ex vivo gene editing, which could decrease the latency for therapeutic intervention, along with the ability to be cryopreserved, which could make it a scalable treatment option for bone marrow transplantation.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
